These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 35282741)

  • 41. Discontinuation of first-line disease-modifying therapy in relapse onset multiple sclerosis.
    Coerver EME; Bourass A; Wessels MHJ; van Kempen ZLE; Jasperse MMS; Tonino BAR; Barkhof F; Mostert J; Uitdehaag BMJ; Killestein J; Strijbis EMM
    Mult Scler Relat Disord; 2023 Jun; 74():104706. PubMed ID: 37068370
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta.
    Paolillo A; Pozzilli C; Giugni E; Tomassini V; Gasperini C; Fiorelli M; Mainero C; Horsfield M; Galgani S; Bastianello S; Buttinelli C
    Eur J Neurol; 2002 Nov; 9(6):645-55. PubMed ID: 12453081
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sustained disease remission after discontinuation of disease modifying treatments in relapsing-remitting multiple sclerosis.
    Pasca M; Forci B; Mariottini A; Mechi C; Barilaro A; Massacesi L; Repice AM
    Mult Scler Relat Disord; 2021 Jan; 47():102591. PubMed ID: 33142245
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Age and sex as determinants of treatment decisions in patients with relapsing-remitting MS.
    Sorensen PS; Kopp TI; Joensen H; Olsson A; Sellebjerg F; Magyari M
    Mult Scler Relat Disord; 2021 May; 50():102813. PubMed ID: 33578207
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Olfactory Dysfunction and Cognition in Radiologically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis.
    Arici Duz O; Saatci O; Karakulak EZ; Birday E; Hanoglu L
    Eur Neurol; 2021; 84(3):175-182. PubMed ID: 33831865
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.
    Burt RK; Balabanov R; Burman J; Sharrack B; Snowden JA; Oliveira MC; Fagius J; Rose J; Nelson F; Barreira AA; Carlson K; Han X; Moraes D; Morgan A; Quigley K; Yaung K; Buckley R; Alldredge C; Clendenan A; Calvario MA; Henry J; Jovanovic B; Helenowski IB
    JAMA; 2019 Jan; 321(2):165-174. PubMed ID: 30644983
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
    Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
    Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy, safety and patient reported outcomes in patients with active relapsing multiple sclerosis treated with ocrelizumab: Final results from the PRO-MSACTIVE study.
    Manchon E; Laplaud D; Vukusic S; Labauge P; Moreau T; Kobelt G; Grouin JM; Lotz M; Pau D; Christine LF
    Mult Scler Relat Disord; 2022 Dec; 68():104109. PubMed ID: 36007299
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western Austria.
    Bsteh G; Algrang L; Hegen H; Auer M; Wurth S; Di Pauli F; Deisenhammer F; Berger T
    Mult Scler; 2020 Jan; 26(1):69-78. PubMed ID: 30507345
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.
    Baldi E; Guareschi A; Vitetta F; Senesi C; Curti E; Montepietra S; Simone AM; Immovilli P; Caniatti L; Tola MR; Pesci I; Montanari E; Sola P; Granella F; Motti L; Ferraro D
    Curr Med Res Opin; 2014 Sep; 30(9):1849-55. PubMed ID: 24831186
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab.
    Dekker I; Leurs CE; Hagens MHJ; van Kempen ZLE; Kleerekooper I; Lissenberg-Witte BI; Barkhof F; Uitdehaag BMJ; Balk LJ; Wattjes MP; Killestein J
    Mult Scler Relat Disord; 2019 Aug; 33():82-87. PubMed ID: 31174043
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis.
    Fisniku LK; Brex PA; Altmann DR; Miszkiel KA; Benton CE; Lanyon R; Thompson AJ; Miller DH
    Brain; 2008 Mar; 131(Pt 3):808-17. PubMed ID: 18234696
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.
    Barkhof F; Kappos L; Wolinsky JS; Li DKB; Bar-Or A; Hartung HP; Belachew S; Han J; Julian L; Sauter A; Napieralski J; Koendgen H; Hauser SL
    Neurology; 2019 Nov; 93(19):e1778-e1786. PubMed ID: 31484710
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.
    Havrdova E; Giovannoni G; Gold R; Fox RJ; Kappos L; Phillips JT; Okwuokenye M; Marantz JL
    Eur J Neurol; 2017 May; 24(5):726-733. PubMed ID: 28328179
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis.
    Prosperini L; Mancinelli C; Haggiag S; Cordioli C; De Giglio L; De Rossi N; Galgani S; Rasia S; Ruggieri S; Tortorella C; Pozzilli C; Gasperini C
    J Neurol Neurosurg Psychiatry; 2020 Mar; 91(3):271-277. PubMed ID: 31974130
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluating the impact of early vs delayed ofatumumab initiation and estimating the long-term outcomes of ofatumumab vs teriflunomide in relapsing multiple sclerosis patients in Spain.
    Vudumula U; Patidar M; Gudala K; Karpf E; Adlard N
    J Med Econ; 2023; 26(1):11-18. PubMed ID: 36472139
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Framework for personalized prediction of treatment response in relapsing remitting multiple sclerosis.
    Stühler E; Braune S; Lionetto F; Heer Y; Jules E; Westermann C; Bergmann A; van Hövell P;
    BMC Med Res Methodol; 2020 Feb; 20(1):24. PubMed ID: 32028898
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies.
    Giovannoni G; Comi G; Rammohan K; Rieckmann P; Dangond F; Keller B; Jack D; Vermersch P
    Adv Ther; 2021 Sep; 38(9):4975-4985. PubMed ID: 34370275
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk of secondary progressive multiple sclerosis: A longitudinal study.
    Fambiatos A; Jokubaitis V; Horakova D; Kubala Havrdova E; Trojano M; Prat A; Girard M; Duquette P; Lugaresi A; Izquierdo G; Grand'Maison F; Grammond P; Sola P; Ferraro D; Alroughani R; Terzi M; Hupperts R; Boz C; Lechner-Scott J; Pucci E; Bergamaschi R; Van Pesch V; Ozakbas S; Granella F; Turkoglu R; Iuliano G; Spitaleri D; McCombe P; Solaro C; Slee M; Ampapa R; Soysal A; Petersen T; Sanchez-Menoyo JL; Verheul F; Prevost J; Sidhom Y; Van Wijmeersch B; Vucic S; Cristiano E; Saladino ML; Deri N; Barnett M; Olascoaga J; Moore F; Skibina O; Gray O; Fragoso Y; Yamout B; Shaw C; Singhal B; Shuey N; Hodgkinson S; Altintas A; Al-Harbi T; Csepany T; Taylor B; Hughes J; Jun JK; van der Walt A; Spelman T; Butzkueven H; Kalincik T
    Mult Scler; 2020 Jan; 26(1):79-90. PubMed ID: 31397221
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Confavreux C; O'Connor P; Comi G; Freedman MS; Miller AE; Olsson TP; Wolinsky JS; Bagulho T; Delhay JL; Dukovic D; Truffinet P; Kappos L;
    Lancet Neurol; 2014 Mar; 13(3):247-56. PubMed ID: 24461574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.